Ventyx Biosciences (NASDAQ:VTYX) Price Target Raised to $14.00

Ventyx Biosciences (NASDAQ:VTYX) had its price objective upped by Wells Fargo & Company from $11.00 to $14.00 in a report issued on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also commented on the stock. Wall Street Zen upgraded shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. Oppenheimer boosted their target price on Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. Finally, HC Wainwright raised Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Wednesday. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.50.

Ventyx Biosciences Stock Down 5.3%

Shares of NASDAQ:VTYX opened at $8.77 on Friday. The business’s 50 day moving average is $4.21 and its 200 day moving average is $2.93. Ventyx Biosciences has a 12-month low of $0.78 and a 12-month high of $9.50. The stock has a market cap of $625.39 million, a price-to-earnings ratio of -5.85 and a beta of 1.21.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13. As a group, equities research analysts expect that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Ventyx Biosciences

Several institutional investors have recently added to or reduced their stakes in VTYX. Hudson Bay Capital Management LP purchased a new position in shares of Ventyx Biosciences in the second quarter valued at about $34,000. Persistent Asset Partners Ltd purchased a new position in Ventyx Biosciences during the 3rd quarter valued at about $51,000. Pallas Capital Advisors LLC bought a new position in Ventyx Biosciences during the 2nd quarter valued at approximately $38,000. Engineers Gate Manager LP purchased a new stake in Ventyx Biosciences in the 2nd quarter worth approximately $42,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Ventyx Biosciences in the first quarter valued at $28,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.